🔴 Chemours is trading 10.1% down today after Q2 earnings miss and weak Q3 EBITDA outlook

Chemours is trading 10.1% down at $16.12 after missing Q2 2026 revenue and EPS expectations and issuing a soft outlook for the upcoming quarter.

• The company reported a 1% year-over-year sales decline and a continued GAAP net loss, driven largely by refrigerant inventory headwinds.
• Guidance for Q3 2026 calls for lower sequential adjusted EBITDA, which has overshadowed recent performance strength in high-growth specialty markets.